Intra-Cellular Therapies, Inc.
ITCI
Rang in aandelen
#1692
Intra-Cellular Therapies, Inc. is a biopharmaceutical company focused on... Intra-Cellular Therapies, Inc. is a biopharmaceutical company focused on creating innovative treatments for conditions affecting the brain and nervous system. The company achieves this by targeting the intricate cellular communication pathways within the central nervous system, primarily operating in the United States. Its commercialized product is CAPLYTA, an approved therapy for schizophrenia in adult patients. Furthermore, the company maintains a robust development pipeline, including lumateperone, which is undergoing late-stage (Phase III) clinical trials for bipolar depression and is also being investigated for autism spectrum disorder and various sleep disturbances associated with neuropsychiatric and neurological illnesses. Other key drug candidates in its pipeline include Lenrispodun (ITI-214), aimed at treating Parkinson's disease and heart failure; ITI-1284-ODT-SL, designed to address neuropsychiatric disorders and behavioral challenges in dementia; and ITI-333, intended for substance use disorders, pain management, and co-occurring psychiatric conditions like depression and anxiety. Established in 2002, Intra-Cellular Therapies, Inc. has its headquarters situated in New York, New York.
Aandeelprijs
$131.87
Laatst gesynchroniseerd: 2025-04-02
Marktkapitalisatie
$12.68B
Verandering (1 dag)
0.00%
Verandering (1 jaar)
0.00%
Land
US
Handel Intra-Cellular Therapies, Inc. (ITCI)
Categorie
Healthcare
EPS voor Intra-Cellular Therapies, Inc. (ITCI)
EPS per December 2024 TTM: $-0.01
Volgens de laatste financiële rapporten en de aandelenkoers van Intra-Cellular Therapies, Inc. is de huidige EPS van het bedrijf (TTM) $-0.01. Eind 2023 had het bedrijf een EPS van $-1.46, een daling ten opzichte van de EPS van 2022 die $-2.72 bedroeg.
EPS-geschiedenis van Intra-Cellular Therapies, Inc. van 2013 tot 2026
EPS aan het einde van elk jaar
| Jaar | EPS | Wijzigen |
|---|---|---|
| 2026 (TTM) | $-0.01 | -98.61% |
| 2024 | $-0.72 | -50.68% |
| 2023 | $-1.46 | -46.32% |
| 2022 | $-2.72 | -22.29% |
| 2021 | $-3.50 | 8.36% |
| 2020 | $-3.23 | 20.52% |
| 2019 | $-2.68 | -5.63% |
| 2018 | $-2.84 | 33.96% |
| 2017 | $-2.12 | -21.19% |
| 2016 | $-2.69 | -7.56% |
| 2015 | $-2.91 | 171.96% |
| 2014 | $-1.07 | -31.41% |
| 2013 | $-1.56 | 0.00% |
EPS van vergelijkbare bedrijven of concurrenten
| Bedrijf | EPS | EPS-verschil | Land |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| $0.56 | -5,663.00% |
IN
|
